Soluble receptor of advanced glycation end product as a biomarker in neurocognitive and neuropsychiatric disorders: A meta-analysis of controlled studies

IF 4.4 3区医学 Q1 MEDICINE, GENERAL & INTERNAL European Journal of Clinical Investigation Pub Date : 2024-05-03 DOI:10.1111/eci.14232

Ghazaleh Nameni, Shima Jazayeri, Somaye Fatahi, Sanaz Jamshidi, Marsa Zaroudi

{"title":"Soluble receptor of advanced glycation end product as a biomarker in neurocognitive and neuropsychiatric disorders: A meta-analysis of controlled studies","authors":"Ghazaleh Nameni, Shima Jazayeri, Somaye Fatahi, Sanaz Jamshidi, Marsa Zaroudi","doi":"10.1111/eci.14232","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background & Objectives</h3>\n \n <p>Currently, there is a significant focus on the decrease of soluble receptor of advanced glycation end products (sRAGE) in neurocognitive and neuropsychiatric disorders. sRAGE plays a decoy role against the inflammatory response of advanced glycation end products (AGE), which has led to increased interest in its role in these disorders. This meta-analysis aimed to investigate the significant differences in sRAGE levels between neurocognitive and neuropsychiatric disorders compared to control groups.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>A systematic review was conducted using the PUBMED, Scopus and Embase databases up to October 2023. Two reviewers assessed agreement for selecting papers based on titles and abstracts, with kappa used to measure agreement and finally publications were scanned according to controlled studies. Effect sizes were calculated as weighted mean differences (WMD) and pooled using a random effects model. Heterogeneity was assessed using I<sup>2</sup>, followed by subgroup analysis and meta-regression tests. Quality assessment was performed using the Newcastle-Ottawa Quality Assessment Scale.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In total, 16 studies were included in the present meta-analysis. Subjects with neurocognitive (<i>n</i> = 1444) and neuropsychiatric (<i>n</i> = 444) disorders had lower sRAGE levels in case–control (WMD: −0.21, 95% CI: −0.33, −0.10; <i>p</i> <.001) and cross-sectional (WMD: −0.29, 95% CI = −0.44, −0.13, <i>p</i> <.001) studies with high heterogeneity and no publication bias. In subgroup analysis, subjects with cognitive impairment (WMD: −0.87, 95% CI: −1.61, −0.13, <i>p</i> =.000), and age >50 years (WMD: −0.39, 95% CI: −0.74, −0.05, <i>p</i> =.000), had lower sRAGE levels in case–control studies. Also, dementia patients (WMD: −0.41, 95% CI: −0.72, −0.10, <i>p</i> =.014) with age >50 years (WMD: −0.33, 95% CI: −0.54, −0.13, <i>p</i> = 0.000) and in Asian countries (WMD: −0.28, 95% CI: −0.42, −0.13, <i>p</i> =.141) had lower sRAGE levels in cross-sectional studies.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This meta-analysis revealed a significant reduction in sRAGE in neurocognitive and neuropsychiatric disorders particularly in Asians and moderate age.</p>\n </section>\n </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":null,"pages":null},"PeriodicalIF":4.4000,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/eci.14232","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background & Objectives

Currently, there is a significant focus on the decrease of soluble receptor of advanced glycation end products (sRAGE) in neurocognitive and neuropsychiatric disorders. sRAGE plays a decoy role against the inflammatory response of advanced glycation end products (AGE), which has led to increased interest in its role in these disorders. This meta-analysis aimed to investigate the significant differences in sRAGE levels between neurocognitive and neuropsychiatric disorders compared to control groups.

Method

A systematic review was conducted using the PUBMED, Scopus and Embase databases up to October 2023. Two reviewers assessed agreement for selecting papers based on titles and abstracts, with kappa used to measure agreement and finally publications were scanned according to controlled studies. Effect sizes were calculated as weighted mean differences (WMD) and pooled using a random effects model. Heterogeneity was assessed using I², followed by subgroup analysis and meta-regression tests. Quality assessment was performed using the Newcastle-Ottawa Quality Assessment Scale.

Results

In total, 16 studies were included in the present meta-analysis. Subjects with neurocognitive (n = 1444) and neuropsychiatric (n = 444) disorders had lower sRAGE levels in case–control (WMD: −0.21, 95% CI: −0.33, −0.10; p <.001) and cross-sectional (WMD: −0.29, 95% CI = −0.44, −0.13, p <.001) studies with high heterogeneity and no publication bias. In subgroup analysis, subjects with cognitive impairment (WMD: −0.87, 95% CI: −1.61, −0.13, p =.000), and age >50 years (WMD: −0.39, 95% CI: −0.74, −0.05, p =.000), had lower sRAGE levels in case–control studies. Also, dementia patients (WMD: −0.41, 95% CI: −0.72, −0.10, p =.014) with age >50 years (WMD: −0.33, 95% CI: −0.54, −0.13, p = 0.000) and in Asian countries (WMD: −0.28, 95% CI: −0.42, −0.13, p =.141) had lower sRAGE levels in cross-sectional studies.

Conclusion

This meta-analysis revealed a significant reduction in sRAGE in neurocognitive and neuropsychiatric disorders particularly in Asians and moderate age.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

作为神经认知和神经精神疾病生物标志物的高级糖化终产物可溶性受体：对照研究荟萃分析

背景& 目的目前，高级糖化终产物可溶性受体（sRAGE）在神经认知和神经精神疾病中的降低受到了广泛关注。sRAGE在高级糖化终产物（AGE）的炎症反应中发挥着诱饵作用，这使得人们对其在这些疾病中的作用越来越感兴趣。本荟萃分析旨在研究神经认知障碍和神经精神障碍患者的sRAGE水平与对照组相比存在的显著差异。方法使用PUBMED、Scopus和Embase数据库对截至2023年10月的研究进行了系统综述。两名审稿人根据标题和摘要对论文的选择进行评估，用卡帕（kappa）来衡量一致性，最后根据对照研究对出版物进行扫描。效应大小以加权平均差（WMD）计算，并使用随机效应模型进行汇总。使用 I2 评估异质性，然后进行亚组分析和元回归测试。采用纽卡斯尔-渥太华质量评估量表进行质量评估。结果本次荟萃分析共纳入 16 项研究。在病例对照（WMD：-0.21，95% CI：-0.33，-0.10；p <.001）和横断面（WMD：-0.29，95% CI=-0.44，-0.13，p <.001）研究中，神经认知障碍（n = 1444）和神经精神障碍（n = 444）受试者的 sRAGE 水平较低，异质性较高，无发表偏倚。在亚组分析中，在病例对照研究中，认知障碍受试者（WMD：-0.87，95% CI：-1.61，-0.13，p =.000）和 50 岁受试者（WMD：-0.39，95% CI：-0.74，-0.05，p =.000）的 sRAGE 水平较低。此外，年龄在 50 岁（WMD：-0.33，95% CI：-0.54，-0.13，p = 0.000）和亚洲国家（WMD：-0.28，95% CI：-0.42，-0.13，p = 0.000）的痴呆症患者（WMD：-0.41，95% CI：-0.72，-0.10，p =.014）的 sRAGE 水平较低。结论这项荟萃分析表明，神经认知和神经精神障碍患者的 sRAGE 水平显著降低，尤其是亚洲人和中年人。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

European Journal of Clinical Investigation 医学-医学：内科

CiteScore

9.50

自引率

3.60%

发文量

192

审稿时长

1 months

期刊介绍： EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.